UK fines for Advanz, others over thyroid drug upheld on appeal, CMA says
MLex Summary: Fines against companies including drugmaker Advanz and private equity group Cinven over thyroid drug pricing were upheld by the UK Court of Appeal in a ruling today, the competition...To view the full article, register now.
Already a subscriber? Click here to view full article